Endoglin (CD105) is an accessory protein of the transforming growth factor-β receptor
system expressed on vascular endothelial cells. Mutation of the endoglin gene is associated …

Targeting of tumor vasculature is a promising strategy for cancer treatment. Among
endothelial cell markers, Endoglin, a cell membrane glycoprotein, is emerging as an …

Endoglin (CD105) is an accessory receptor for transforming growth factor beta (TGF-β) and
its expression is up-regulated in actively proliferating endothelial cells. Endoglin has been …

Among surface molecules expressed on endothelial cells, endoglin (CD105) is emerging as
a prime vascular target for antiangiogenetic cancer therapy. CD105 is a cell membrane …

Endoglin/CD105 is a membrane protein involved in the TGF‐β receptor signalling pathway.
Endoglin expression has been reported to be selective for a few cell types, in particular …

Endoglin (CD105) is an auxiliary membrane receptor of transforming growth factor beta
(TGF‐β) that interacts with type I and type II TGF‐β receptors and modulates TGF‐β …

Angiogenesis is crucial for tumor development and progression, and antiangiogenetic
therapy represents a promising approach for cancer treatment. Thus, the in-depth …

Increasing evidence suggests that endoglin (CD105) is a new powerful marker of
neovascularization in solid malignancies; thus, using breast cancer as a model, we …

Endoglin (CD105) is a cell membrane glycoprotein over‐expressed on highly proliferating
endothelial cells in culture, and on endothelial cells of angiogenetic blood vessels within …

We have characterized a murine IgM monoclonal antibody, TEC-11, that recognizes
endoglin and may be suitable for targeting cytotoxic agents to human tumor vasculature …